InnoSer News
Relevant in vivo studies and in vitro immuno-oncology assays
Drug efficacy in vivo studies At InnoSer, we frequently carry out in vivo efficacy studies in a range of preclinical models (patient-derived xenografts, syngeneic models, cell-line derived xenografts) complemented with readouts such immune cell profiling and...
Assessment of Disease Progression in the ADPKD Mouse Model
A significant challenge in the ADPKD research field is demonstrating efficacy of novel compounds in preclinical research models using clinically relevant endpoints. To date, total kidney volume (TKV) is the only FDA and EMA-approved imaging biomarker that is used as a...
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline.
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline. Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services,...
The Application of Bioluminescence Imaging in Preclinical Oncology Research and Beyond
Introduction into the power of bioluminescence imaging Bioluminescence imaging (further referred to as BLI in this article) is an in vivo imaging technique that allows non-invasive longitudinal monitoring of in vivo processes, commonly applied in preclinical oncology...
Latest cardiovascular and metabolic research news
InnoSer offers a selection of gold standard cardio-metabolic disease models in rodents, supporting custom studies to optimize the preclinical development of your drug candidates. Learn more about you can leverage InnoSer’s experience and expertise in the...
PK/PD and Tolerability Testing in the ADPKD Mouse Model
The lead optimisation phase is a crucial process during which you investigate and select the most promising preclinical candidate(s) to progress to efficacy testing using animal models of human diseases. Pharmacokinetic (PK) and Pharmacodynamic (PD) profiling helps...
In vivo Tumorigenicity Testing to Evaluate Your Therapeutics’ Safety
For all novel therapy types in the immuno-oncology field such as immunotherapies, small molecule, biologics, ATMPs, gene therapeutics etc., rigorous preclinical research is the key to success in clinical trials. Learn more about how InnoSer’s expertise in the...
How to obtain the most value out of your neurodegenerative disease research models?
To date, large ongoing efforts are being made to provide well-characterised animal models which are suitable for investigating novel therapeutics. To ensure full confidence in the efficacy profile of novel therapeutic agents, efficacy testing often needs to be...
InnoSer to Present Novel Data at AD/PD 2024 Showcasing in Vitro Neurodegenerative Disease Modelling Capabilities
We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO), will be actively participating in the upcoming AD/PD 2024 Conference taking place in Lisbon, Portugal on March 5-9, 2024. The theme of AD/PD 2024 is striving...